- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03863132
역류성 저유량 저구도 대동맥판막 협착증의 경피적 판막 봉합 유무에 관계없이 최적의 내과적 치료의 정확한 이득 평가 (REBOOT-PARADOX)
증상이 있는 역설적 저유량 저경도 대동맥판막 협착증 환자에서 판막 수리 유무에 따른 최적의 내과적 치료 - 다기관 무작위 비교
Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.
연구 개요
상세 설명
Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.
Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.
REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Baden-Wurttemberg
-
Tübingen, Baden-Wurttemberg, 독일, 72076
- Universitätsklinikum Tübingen
-
-
Bavaria
-
München, Bavaria, 독일, 80636
- Deutsches Herzzentrum München
-
München, Bavaria, 독일, 81377
- Klinikum der Universität München-Großhadern
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, 독일, 20246
- Universitäres Herz- u. Gefäßzentrum Hamburg
-
-
Hesse
-
Bad Nauheim, Hesse, 독일
- Kerckhoff-Klinik GmbH
-
-
Lower Saxony
-
Bad Bevensen, Lower Saxony, 독일, 29549
- Herz- und Gefäßzentrum Bad Bevensen
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, 독일, 18057
- Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, 독일, 32545
- Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen
-
Cologne, North Rhine-Westphalia, 독일, 50937
- Herzzentrum der Universität Köln
-
-
Rhineland-Palatinate
-
Ludwigshafen am Rhein, Rhineland-Palatinate, 독일
- Klinikum der Stadt Ludwigshafen a. Rh.
-
-
Saxony
-
Leipzig, Saxony, 독일
- Herzzentrum Leipzig
-
-
Schleswig-Holstein
-
Bad Segeberg, Schleswig-Holstein, 독일
- Segeberger Kliniken, Herzzentrum
-
-
-
-
-
Zurich, 스위스, 8091
- Universitätsspital Zürich, Universitätres Herzzentrum Zürich
-
-
-
-
-
Milan, 이탈리아, 20089
- Humanitas Mirasole S.P.A
-
Pisa, 이탈리아, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years
- I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient < 40 mmHg and stroke volume index (SVI) < 35ml/m2
- I3. Left ventricular ejection fraction ≥ 50%
- I4. MDCT aortic valve calcium score men > 2000AU, women > 1200AU OR the likelihood criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age < 70 yrs., AVS < 0.8 cm2; SVI < 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV longitudinal function without other reason)
- I5. Heart team agrees on eligibility for TAVR
- I6. Written informed consent
- I7. Negative pregnancy test in women with childbearing potential
Exclusion Criteria:
- E1. Hemodynamic instability
- E2. Cardiogenic shock
- E3. Pre-existing mechanical or bio-prosthetic valve in any position
- E4. Concomitant severe valvular heart disease
- E5. Pre-existing or active endocarditis
- E6. Need for heart surgery due to other conditions
- E7. Aortic valve is congenital unicuspid or congenital bicuspid
- E8. Hypertrophic cardiomyopathy with or without obstruction
- E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- E10. Acute myocardial infarction within 1 month before intended AS-treatment
- E11. Renal replacement therapy
- E12. Estimated life expectancy < 24 months (730 days) due to carcinomas end stage liver disease or renal disease
- E13. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- E14. Patient refuses aortic valve repair
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: TAVR Group
Patients will be treated by transcatheter aortic valve repair (TAVR). |
Repair of defective aortic valve by microsurgical Intervention. |
|
간섭 없음: Medical Treatment Group
Patients will receive optimal medical treatment alone. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to death
기간: 24 months after last-patient-in
|
All-cause mortality |
24 months after last-patient-in
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cardiovascular mortality
기간: 5 years after index treatment
|
Death because of cardiovascular events |
5 years after index treatment
|
|
Re-hospitalization due to heart failure
기간: 5 years after index treatment
|
Number of hospital stays after randomization |
5 years after index treatment
|
|
Incidence of neurological events - incidence of strokes
기간: 5 years after randomization
|
Number of strokes |
5 years after randomization
|
|
Incidence of neurological Events - incidence of transient ischaemic attacks
기간: 5 years after randomization
|
Number of transient ischaemic attacks |
5 years after randomization
|
|
Cardiac functionality - left ventricular function
기간: 5 years after randomization
|
Echocardiographic measurement of left ventricular ejection fraction in % |
5 years after randomization
|
|
Cardiac functionality - aortic valve hemodynamics
기간: 5 years after randomization
|
Measurement of aortic pressure in mmHg |
5 years after randomization
|
|
Patients' quality of life
기간: 5 years after randomization
|
EQ5D-score in % |
5 years after randomization
|
|
Device reliability
기간: 5 years after randomization
|
Number of reinterventions (TAVR arm only) |
5 years after randomization
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Steffen Massberg, Prof. Dr., University Clinic Munich
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- REBOOT-PARADOX
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .